Chemotherapy News and Research

Latest Chemotherapy News and Research

Researchers create artificial human ovary to yield infertility treatments for cancer patients

Researchers at Brown University and Women & Infants Hospital have invented the first artificial human ovary, an advance that provides a potentially powerful new means for conducting fertility research and could also yield infertility treatments for cancer patients. The team has already used the lab-grown organ to mature human eggs.

15 Sep 2010

Data from Phase II trial of zanolimumab in PTCL published in British Journal of Haematology

TenX Biopharma, Inc. announced today that data from a Phase II trial of zanolimumab (HuMax-CD4®) in peripheral T-cell Lymphoma were published in the British Journal of Haematology (Sep 2010: 150(5):565-73). The Hx-CD4-109 trial was designed to evaluate the safety and efficacy of zanolimumab in patients who have relapsed or refractory non-cutaneous peripheral T-cell lymphoma.

14 Sep 2010

More adults washing hands in public restrooms

In the latest observational study sponsored by the American Society for Microbiology and the American Cleaning Institute- (formerly The Soap and Detergent Association), 85% of adults washed their hands in public restrooms, compared with 77% in 2007. The 85% total was actually the highest observed since these studies began in 1996. The results were announced at the Interscience Conference on Antimicrobial Agents and Chemotherapy, an infectious disease meeting sponsored by the American Society for Microbiology.

14 Sep 2010

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Gilead Sciences, Inc. today announced Phase II clinical trial results showing that its investigational fixed-dose, single-tablet "Quad" regimen of elvitegravir, cobicistat and Truvada (emtricitabine and tenofovir disoproxil fumarate) for the treatment of HIV infection maintained a high rate of virologic suppression through 48 weeks, exhibiting antiretroviral activity comparable to that of Atripla(efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg).

14 Sep 2010

Progenics Pharmaceuticals presents findings of humanized monoclonal antibodies against C. difficile bacterium

Progenics Pharmaceuticals, Inc. today presented preclinical findings for its humanized monoclonal antibodies against the disease-causing toxins produced by the bacterium Clostridium difficile.

14 Sep 2010

Researchers focus on finding markers to detect atypical vascular lesions that lead to angiosarcomato

Physicians have long noticed that breast cancer patients who have had surgery or radiation therapy have an heightened risk of developing angiosarcoma, a rare type of cancer that originates in the lining of the blood vessels.

14 Sep 2010

Notch1 protein impacts childhood leukemia progression: Study

A protein crucial for the immune response appears to be a key player in the progression of a devastating form of childhood leukemia called T-cell acute lymphoblastic leukemia (T-ALL). Suppressing the activity of the protein kills the leukemic cells, the study shows, opening a potential avenue to new drugs that could prevent progression of the disease.

14 Sep 2010

Genmab, Seattle Genetics enter ADC research collaboration agreement

Genmab A/S and Seattle Genetics, Inc. announced today that the companies have entered into an antibody-drug conjugate (ADC) research collaboration agreement.

14 Sep 2010

MSKCC to open new 7,745-square-foot outpatient chemotherapy center in Brooklyn

Memorial Sloan-Kettering Cancer Center (MSKCC) today celebrated a new outpatient chemotherapy center, which is scheduled to open later this month, pending approval from the State Department of Health. The 7,745-square-foot facility, called the Brooklyn Infusion Center, will provide leading-edge chemotherapy services to current MSKCC patients who live in or near Brooklyn — which amounts to more than 15 percent of MSKCC's patients currently being treated in Manhattan.

14 Sep 2010

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

Rib-X Pharmaceuticals, Inc., a development-stage antibiotics company with a broad product pipeline based on its innovative discovery platform, today announced the presentation of positive preclinical data for delafloxacin in four poster sessions at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

14 Sep 2010

Researchers identify body's control switch system to eliminate damaged cells

St. Jude Children's Research Hospital scientists discovered a new mechanism cells use to maximize production of a key protein following DNA damage and demonstrated the potential of small molecules to regulate the process and protect healthy tissue.

14 Sep 2010

Platinum and light together fight cancer

Researchers continue to search for cancer treatments that effectively destroy tumor cells while protecting surrounding healthy tissue and the body. One intriguing approach involves photoactivated drugs: an inactive precursor would be administered, then the diseased tissue could be irradiated to convert the drug into its cytotoxic form locally.

14 Sep 2010

Molecule microRNA-21 enhances growth and survival of existing lung cancer

A tiny molecule that spurs the progression of non-small-cell lung cancer could become a player in fighting the disease, say researchers at UT Southwestern Medical Center, who published a study on how the molecule behaves in mice in the Sept. 14 issue of Cancer Cell.

14 Sep 2010

Excelimmune presents positive results for HRPA therapy against MRSA infections

Excelimmune, Inc. announced positive results from preclinical studies evaluating the efficacy of its human recombinant polyclonal antibody (HRPA) therapy against infections caused by methicillin-resistant Staphylococcus aureus (MRSA).

14 Sep 2010

OSUCCC-James researchers identify experimental agent that targets chronic lymphocytic leukemia

Researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC-James) have identified an experimental agent that targets chronic lymphocytic leukemia and perhaps other proliferative disorders of lymphocytes.

14 Sep 2010

Trius Therapeutics reports torezolid antibiotic resistance mechanism for MRSA strains

Trius Therapeutics, Inc. today reported new findings on torezolid phosphate (TR-701), a second generation oxazolidinone antibiotic now in Phase 3 clinical development. The data elucidate the mechanism by which torezolid retains full activity against clinical isolates of Staphylococcus aureus (S. aureus) carrying the cfr gene which confers resistance to first generation oxazolidinones such as linezolid, marketed by Pfizer as Zyvox.

14 Sep 2010

Experts warn dip in antibiotic R&D could lead to treatment challenges

The 50th annual meeting of the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) kicked off in Boston on Sunday with experts warning that a "slowdown" in research on antibiotic development could result in treatment challenges.

14 Sep 2010

ADHD medication improves childhood cancer survivors: Research

A medicine widely used to treat attention-deficit/hyperactivity disorder (ADHD) also provides long-term relief from the attention and behavior changes that affect many childhood cancer survivors, according to a multicenter trial led by St. Jude Children's Research Hospital investigators.

14 Sep 2010

Study finds new therapeutic target for polycystic kidney disease

In work suggesting a new approach to treating polycystic kidney disease (PKD), a leading cause of kidney failure, researchers at Children's Hospital Boston were able to block the formation of fluid-filled cysts, the hallmark of the disease, in a mouse model. Their findings, using a compound that inhibits a receptor known as c-Met, will be published in the September 13th online edition of the Journal of Clinical Investigation.

14 Sep 2010

Tetraphase Pharmaceuticals presents TP-434 drug candidate clinical data

Tetraphase Pharmaceuticals, Inc., yesterday presented new clinical and preclinical data for its lead drug candidate, TP-434, which demonstrated the novel antibiotic as a once daily intravenous (I.V.) monotherapy capable of treating multidrug-resistant gram-negative pathogens while also having potency and broad spectrum coverage of other serious and multidrug resistant gram-positive pathogens.

13 Sep 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Researchers create artificial human ovary to yield infertility treatments for cancer patients

Data from Phase II trial of zanolimumab in PTCL published in British Journal of Haematology

More adults washing hands in public restrooms

Gilead Sciences announces Quad regimen Phase II clinical trial results for HIV infection treatment

Progenics Pharmaceuticals presents findings of humanized monoclonal antibodies against C. difficile bacterium

Researchers focus on finding markers to detect atypical vascular lesions that lead to angiosarcomato

Notch1 protein impacts childhood leukemia progression: Study

Genmab, Seattle Genetics enter ADC research collaboration agreement

MSKCC to open new 7,745-square-foot outpatient chemotherapy center in Brooklyn

Rib-X Pharmaceuticals presents positive preclinical data for delafloxacin at ICAAC Conference

Researchers identify body's control switch system to eliminate damaged cells

Platinum and light together fight cancer

Molecule microRNA-21 enhances growth and survival of existing lung cancer

Excelimmune presents positive results for HRPA therapy against MRSA infections

OSUCCC-James researchers identify experimental agent that targets chronic lymphocytic leukemia

Trius Therapeutics reports torezolid antibiotic resistance mechanism for MRSA strains

Experts warn dip in antibiotic R&D could lead to treatment challenges

ADHD medication improves childhood cancer survivors: Research

Study finds new therapeutic target for polycystic kidney disease

Tetraphase Pharmaceuticals presents TP-434 drug candidate clinical data

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in